How Is PCOS Diagnosed? Signs, Symptoms, and Testing Explained

Why PCOS Is One of the Most Underdiagnosed Conditions in Women

Polycystic ovary syndrome affects between 8% and 13% of women of reproductive age, making it one of the most common endocrine disorders in this population [1]. Despite its prevalence, up to 70% of affected women worldwide remain undiagnosed [1]. The gap between how many women have PCOS and how many know it is staggering.

A Syndrome, Not a Single Disease

PCOS is a syndrome. That means it is defined by a cluster of features rather than a single lab value or imaging finding. Two women with confirmed PCOS can look completely different clinically. One may have acne and regular cycles with elevated testosterone on blood work. Another may have absent periods and cystic ovaries but normal androgen levels. This heterogeneity is one reason the average diagnostic journey takes more than two years and involves visits to three or more clinicians, according to a large international survey published in the Journal of Clinical Endocrinology & Metabolism [2].

Why the Name Is Misleading

The name itself causes confusion. "Polycystic ovaries" are not actually cysts. They are small antral follicles. A woman can have polycystic ovarian morphology on ultrasound and not have PCOS, and a woman can meet full diagnostic criteria without polycystic-appearing ovaries. The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS, endorsed by the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), explicitly notes that the name is a misnomer but retained it due to international recognition [3].

The Rotterdam Criteria: The Diagnostic Standard

The Rotterdam criteria, established in 2003 and reaffirmed by the 2023 international guideline, remain the accepted framework for PCOS diagnosis [3]. A diagnosis requires at least two of three features: oligo-anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound.

Feature 1: Oligo-Anovulation

Oligo-anovulation means irregular, infrequent, or absent ovulation. In clinical practice, this typically presents as menstrual cycles longer than 35 days, fewer than eight cycles per year, or amenorrhea lasting 90 days or more. Cycle irregularity is the most reported symptom, present in roughly 75% of women with PCOS [4].

For adolescents, cycle irregularity is harder to interpret. The 2023 guideline recommends using cycles longer than 45 days or amenorrhea for more than 90 days in adolescents who are more than two years post-menarche, because irregular cycles are physiologically normal in the first one to two years after a girl's first period [3].

Feature 2: Hyperandrogenism

Hyperandrogenism can be clinical, biochemical, or both. Clinical hyperandrogenism includes hirsutism (scored using the modified Ferriman-Gallwey scale, with a score of 4 to 6 or higher considered significant depending on ethnicity), moderate-to-severe acne, or androgenic alopecia [3]. Biochemical hyperandrogenism is defined by elevated levels of total testosterone, free testosterone, or dehydroepiandrosterone sulfate (DHEA-S) on blood work.

The guideline identifies calculated free testosterone and free androgen index (FAI) as the most sensitive biochemical markers [3]. A common pitfall: many standard testosterone assays lack the sensitivity to detect mild elevations in women. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the recommended assay method.

Feature 3: Polycystic Ovarian Morphology

On transvaginal ultrasound using a transducer frequency of 8 MHz or greater, polycystic ovarian morphology is defined as 20 or more follicles (2 to 9 mm in diameter) in at least one ovary, or an ovarian volume of 10 mL or greater [3]. Older thresholds used a cutoff of 12 follicles, but improved ultrasound resolution led to the updated count in the 2023 guideline.

For adolescents or women who cannot undergo transvaginal ultrasound, transabdominal ultrasound is less reliable. The guideline suggests using ovarian volume alone (10 mL or greater) and cautions against relying on follicle counts from transabdominal imaging [3].

Signs and Symptoms That Suggest PCOS

The clinical picture of PCOS extends well beyond ovaries and periods. Recognizing the full range of signs can accelerate diagnosis, particularly for women whose symptoms are dismissed or attributed to other causes.

Menstrual Irregularity

Irregular periods are the hallmark feature. Cycles may be unpredictably long, absent for months, or occasionally very frequent. Some women experience heavy bleeding when menstruation does occur, because prolonged anovulation allows the endometrial lining to build up without the progesterone exposure that normally follows ovulation.

Skin and Hair Changes

Hirsutism affects approximately 60% of women with PCOS globally, though prevalence varies by ethnicity [4]. Excess terminal hair growth along the upper lip, chin, chest, lower abdomen, and inner thighs is driven by elevated androgens. Acne that persists well past adolescence, particularly along the jawline and lower face, is another androgen-mediated sign. Thinning hair at the crown (female pattern hair loss) rounds out the androgenic triad.

Metabolic Warning Signs

Insulin resistance is present in an estimated 50% to 80% of women with PCOS, including many who are not overweight [5]. Weight gain concentrated around the midsection, difficulty losing weight despite caloric restriction, and acanthosis nigricans (dark, velvety patches of skin on the neck, axillae, or groin) all signal insulin resistance. A 2020 meta-analysis in Diabetes Care found that women with PCOS have a fourfold increased risk of developing type 2 diabetes compared with age-matched controls [6].

Mental Health Impact

Depression and anxiety occur at significantly higher rates in women with PCOS. A systematic review of 18 studies (N = 3,050) reported that women with PCOS were nearly three times more likely to screen positive for depressive symptoms compared with controls [7]. The 2023 guideline recommends routine screening for anxiety and depression at diagnosis and at regular intervals thereafter [3].

Blood Tests and Lab Work Used to Diagnose PCOS

Lab testing serves two purposes: confirming biochemical hyperandrogenism and excluding conditions that mimic PCOS. No single blood test diagnoses PCOS. The combination of results, clinical findings, and imaging determines the diagnosis.

Core Androgen Panel

The 2023 guideline recommends measuring total testosterone, calculated free testosterone or free androgen index, and DHEA-S as the initial androgen assessment [3]. Free testosterone is calculated from total testosterone, sex hormone-binding globulin (SHBG), and albumin. SHBG is often suppressed in PCOS, especially when insulin resistance is present, because insulin directly inhibits hepatic SHBG production.

Dr. Robert Barbieri, former chair of obstetrics and gynecology at Harvard Medical School, has noted: "SHBG is a vastly underappreciated biomarker in PCOS. A low SHBG in a woman with irregular cycles is highly suggestive of the diagnosis even when total testosterone is in the normal range" [8].

Exclusionary Labs

The following conditions must be ruled out before a PCOS diagnosis is assigned:

• Thyroid dysfunction: TSH to screen for hypothyroidism or hyperthyroidism
• Hyperprolactinemia: serum prolactin
• Non-classic congenital adrenal hyperplasia (NCAH): early-morning 17-hydroxyprogesterone, drawn in the follicular phase; a level above 200 ng/dL warrants ACTH stimulation testing [9]
• Cushing syndrome: 24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test (only if clinically suspected)
• Androgen-secreting tumors: rapid virilization or total testosterone above 150 to 200 ng/dL should prompt imaging

Optional but Informative Tests

Anti-Mullerian hormone (AMH) reflects the pool of small antral follicles and is consistently elevated in PCOS. A 2021 meta-analysis in Human Reproduction Update (46 studies, N = 10,154) found that AMH had a pooled sensitivity of 79% and specificity of 83% for PCOS diagnosis [10]. The 2023 guideline now includes AMH as an alternative to ultrasound for diagnosis in adult women, particularly when ultrasound is unavailable or unreliable [3]. This is a meaningful shift from prior versions of the guideline.

Fasting glucose and insulin, hemoglobin A1c, and a lipid panel are recommended at the time of diagnosis to assess metabolic risk. A two-hour oral glucose tolerance test (OGTT) is preferred over fasting glucose alone because it detects impaired glucose tolerance, which fasting values often miss in this population [3].

Ultrasound in PCOS Diagnosis: What Doctors Look For

Pelvic ultrasound is one arm of the Rotterdam triad. It is useful but not required for diagnosis if both of the other two features are present.

Transvaginal vs. Transabdominal Approach

Transvaginal ultrasound provides superior resolution. Using a high-frequency probe (8 MHz or greater), the sonographer counts the number of follicles measuring 2 to 9 mm in each ovary and measures ovarian volume. The 2023 threshold is 20 or more follicles in at least one ovary, or ovarian volume of 10 mL or greater [3].

Transabdominal ultrasound is appropriate for adolescents and women who decline or cannot tolerate transvaginal imaging. Because image quality is lower, the guideline advises using only ovarian volume (10 mL or greater) as the morphologic criterion in this setting [3].

When Ultrasound Is Not Needed

If a woman has both oligo-anovulation and hyperandrogenism (clinical or biochemical), the Rotterdam criteria are already met. Ultrasound is not needed to confirm the diagnosis in this scenario. It may still be performed to exclude other pelvic pathology, but its absence does not prevent a diagnosis.

The Role of AMH as an Ultrasound Substitute

As noted above, serum AMH can now serve as an alternative to ultrasound for detecting excess ovarian follicular activity [3]. This is especially practical in primary care settings where gynecologic ultrasound may not be immediately accessible. A single blood draw can simultaneously provide androgen levels, exclusionary labs, and AMH.

Differential Diagnosis: What Else Could It Be?

Several conditions share features with PCOS. Missing one of these mimics can delay proper treatment or lead to an incorrect PCOS label.

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism can cause menstrual irregularity. Hypothyroidism may also raise prolactin, cause weight gain, and slow hair growth. A simple TSH measurement rules this out.

Non-Classic Congenital Adrenal Hyperplasia

NCAH due to 21-hydroxylase deficiency occurs in roughly 1% to 10% of women presenting with hyperandrogenism, depending on the population studied [9]. It presents with hirsutism, acne, and irregular cycles. An early-morning follicular-phase 17-hydroxyprogesterone below 200 ng/dL effectively excludes it. The Endocrine Society's 2018 guideline on congenital adrenal hyperplasia recommends this screening for all women being evaluated for androgen excess [9].

Hyperprolactinemia

Elevated prolactin suppresses gonadotropin-releasing hormone pulsatility, causing oligo-anovulation. Mild prolactin elevations can also occur in PCOS itself, so levels above 50 to 100 ng/mL should prompt MRI to evaluate for a pituitary adenoma.

Hypothalamic Amenorrhea

Functional hypothalamic amenorrhea from energy deficit, excessive exercise, or psychological stress causes anovulation but with low (not elevated) gonadotropins and estradiol. AMH is typically normal or low. Distinguishing this from PCOS matters because the treatment approaches differ entirely.

Cushing Syndrome and Androgen-Secreting Tumors

These are uncommon but serious. Cushing syndrome should be considered when physical findings include proximal muscle wasting, wide purple striae, or easy bruising. Androgen-secreting ovarian or adrenal tumors typically cause rapid-onset virilization over weeks to months, with total testosterone levels exceeding 150 to 200 ng/dL.

PCOS Diagnosis in Special Populations

Standard criteria do not always apply cleanly. Adolescents, women on hormonal contraception, and postmenopausal women each require modified approaches.

Adolescents

The 2023 guideline cautions against premature diagnosis in adolescents [3]. Both irregular cycles and polycystic-appearing ovaries are normal developmental variants in the first years after menarche. In adolescents more than two years post-menarche, the guideline recommends requiring both hyperandrogenism and oligo-anovulation for diagnosis, treating polycystic ovarian morphology alone as insufficient. For those who do not meet full criteria, the term "at risk for PCOS" is suggested, with reassessment in one to three years.

Women on Hormonal Contraception

Combined oral contraceptives suppress gonadotropins, regulate cycles, and lower androgens. This masks all three Rotterdam features. If a woman has been on hormonal contraception for years and wants to know whether she has PCOS, the guideline recommends stopping the contraceptive for at least three months before diagnostic evaluation, using clinical signs and AMH in the interim if a definitive answer is needed sooner [3].

Perimenopause and Beyond

PCOS does not disappear at menopause, but its diagnostic criteria were developed for reproductive-age women. Androgen levels naturally decline with age. The guideline acknowledges that there are no validated diagnostic criteria for PCOS after menopause and recommends a presumptive diagnosis based on a well-documented history of the condition during reproductive years [3].

What Happens After a PCOS Diagnosis

A confirmed diagnosis is the starting point, not the finish line. The 2023 guideline recommends a structured metabolic and psychological assessment at diagnosis.

Baseline Metabolic Screening

All women diagnosed with PCOS should undergo a 75 g oral glucose tolerance test (or hemoglobin A1c if OGTT is not feasible), a fasting lipid panel, and measurement of blood pressure and waist circumference [3]. The European Society of Endocrinology and the Endocrine Society both recommend repeating metabolic screening every one to three years, or more frequently if BMI increases or additional risk factors emerge [11].

Cardiovascular Risk Assessment

A 2010 consensus statement from the Androgen Excess and PCOS Society classified all women with PCOS as being at increased cardiovascular risk [12]. The Rotterdam phenotype that carries the highest metabolic burden includes both hyperandrogenism and oligo-anovulation, regardless of ovarian morphology.

Psychological Screening

The 2023 guideline recommends validated screening tools for depression (PHQ-9), anxiety (GAD-7), and body image disturbance at the time of diagnosis [3]. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on PCOS similarly identifies quality of life and mental health screening as part of standard evaluation [13].

Treatment Planning

Treatment is phenotype-driven. Women seeking fertility receive ovulation induction with letrozole as first-line therapy, per both the 2023 guideline and ACOG [3][13]. Women not seeking pregnancy may use combined oral contraceptives to manage hyperandrogenism and regulate cycles. Metformin addresses insulin resistance and is recommended as an adjunct for metabolic features, particularly when BMI exceeds 25 kg/m² [3]. Lifestyle modification targeting 5% to 10% body weight loss improves ovulation rates, androgen levels, and insulin sensitivity in women with excess weight [3].

The 2023 international guideline's lead author, Professor Helena Teede of Monash University, stated in the guideline's public summary: "PCOS is a lifelong condition that requires a tailored, multidisciplinary approach addressing reproductive, metabolic, and psychological health across the lifespan" [3].